LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

Search

Certara Inc

Fermé

SecteurSoins de santé

11.85 3.49

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.81

Max

12.27

Chiffres clés

By Trading Economics

Revenu

-1.8M

4.7M

Ventes

5.6M

106M

BPA

0.15

Marge bénéficiaire

4.474

Employés

1,487

EBITDA

-25M

609K

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+28.06% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

77M

2.1B

Ouverture précédente

8.36

Clôture précédente

11.85

Sentiment de l'Actualité

By Acuity

50%

50%

195 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Certara Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 mai 2025, 23:59 UTC

Actualités
Résultats

Naver 1Q Net Slumps on Higher Costs

8 mai 2025, 23:39 UTC

Résultats

OCBC 1Q Net Down on Lower Interest Income

8 mai 2025, 23:01 UTC

Résultats

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 mai 2025, 22:52 UTC

Résultats

REA Expects Annual Listings Growth Despite April Decline

8 mai 2025, 22:46 UTC

Résultats

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 mai 2025, 23:41 UTC

Market Talk

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 mai 2025, 23:30 UTC

Résultats

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 mai 2025, 23:29 UTC

Résultats

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 mai 2025, 23:22 UTC

Résultats

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 mai 2025, 23:22 UTC

Résultats

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 mai 2025, 23:21 UTC

Résultats

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 mai 2025, 23:21 UTC

Résultats

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 mai 2025, 23:05 UTC

Market Talk

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 mai 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 23:01 UTC

Actualités

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 mai 2025, 22:28 UTC

Résultats

REA Expects FY 2025 Listings Growth of 1-2%

8 mai 2025, 22:28 UTC

Résultats

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 mai 2025, 22:27 UTC

Résultats

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 mai 2025, 22:27 UTC

Résultats

REA Says April Residential Listings Fell by 11% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Résultats

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 mai 2025, 22:25 UTC

Résultats

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 mai 2025, 22:25 UTC

Résultats

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Comparaison

Variation de prix

Certara Inc prévision

Objectif de Prix

By TipRanks

28.06% hausse

Prévisions sur 12 Mois

Moyen 14.56 USD  28.06%

Haut 18 USD

Bas 9 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

3

Achat

7

Maintien

0

Vente

Score Technique

By Trading Central

11.215 / 12.79Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Weak Bullish Evidence

Sentiment

By Acuity

195 / 382Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.